## (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 31<sup>st</sup> December, 2020

## **ORDER**

S. O. 4773(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

## **Table**

SI. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retai I Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Dapagliflozin + Metformin Hydrochloride Extended- Release Tablet	Each film-coated tablet contains: Dapagliflozin 10mg, Metformin Hydrochloride IP (In Extended release form) 500mg	1 Tablet	M/s Torrent Pharmaceuticals Limited	10.60
2.	Dapagliflozin + Metformin Hydrochloride Extended- Release Tablet	Each film-coated tablet contains: Dapagliflozin 10mg, Metformin Hydrochloride IP (In Extended release form) 1000mg	1 Tablet	M/s Torrent Pharmaceuticals Limited	12.26
3.	Gentamicin Sulphate + Dexamethasone Sodium Phosphate Eye Drop	Each ml contains: Gentamicin Sulphate IP eq. to Gentamicin base 0.3% w/v Dexamethasone Sodium Phosphate IP	1 ml	M/s Skymap Healthcare Pvt. Ltd.	1.47

SI. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retai I Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
		eq. to Dexamethasone Phosphate 0.1% w/v			
4.	Gentamicin Sulphate + Dexamethasone Sodium Phosphate Eye Drop	Each ml contains: Gentamicin Sulphate IP eq. to Gentamicin base 0.3% w/v Dexamethasone Sodium Phosphate IP eq. to Dexamethasone Phosphate 0.1% w/v	1 ml	M/s Skymap Healthcare Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.	1.47
5.	Cefixime Tablets	Each film coated tablet contains: Cefixime IP as Trihydrate eq. to Anhydrous Cefixime 100mg	1 Tablet	M/s Hema Laboratories Pvt. Limited /M/s Sun Pharmaceutical Industries Limited	6.16
6.	Ibuprofen with Paracetamol Suspension	Each 5ml contains: Ibuprofen IP 100mg Pracetamol IP 162.5mg	1 ml	M/s Vivimed Labs Ltd. /M/s Alembic Pharmaceuticals Limited	0.36
7.	Lidocaine Spray 10% w/v	Each ml contains: Lidocaine USP 100mg Ethanol IP 30.4% v/v	1 ml	M/s Zydus Healthcare Limited	8.51

## Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/214/82/2020/F

F. No. 8(82)/2020/D.P./NPPA-Div.-II

(Prasenjit Das) Assistant Director